| Literature DB >> 31852446 |
Shazia Khan1,2,3, Lettie E Rawlins2,4, Gaurav V Harlalka2,5, Muhammad Umair6, Asmat Ullah3,7, Shaheen Shahzad1, Muhammad Javed8, Emma L Baple2,4, Andrew H Crosby2, Wasim Ahmad3, Asma Gul9.
Abstract
BACKGROUND: Neurological disorders are a common cause of morbidity and mortality within Pakistani populations. It is one of the most important challenges in healthcare, with significant life-long socio-economic burden.Entities:
Keywords: Exome sequencing; HEXB; MBOAT7; Neurological disorder; Pakistan; Sandhoff disease
Mesh:
Substances:
Year: 2019 PMID: 31852446 PMCID: PMC6921424 DOI: 10.1186/s12881-019-0907-7
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Fig. 1a Pedigree of family 1, with two affected siblings with Sandhoff disease (filled symbols). Genotype is shown in red under individuals (+, mutant; −, WT). * indicates samples available for analysis. The affected female was shown to be homozygous for the HEXB c.445 + 1G > T splice site variant. b Electropherogram showing the DNA sequence variant (HEXB c.445 + 1G > T) in a homozygous affected individual. c Schematic representation of HEXB exons and position of the genomic variant identified in this study. d-e Pedigrees of families 2 and 3, both from the Khyber Pakhtunkhwa province and with individuals affected with a neurodevelopmental disorder (filled symbols), within the same generation. Genotype is shown in red under individuals (+, mutant; −, WT). * indicates samples available for analysis. Six affected individuals were shown to be homozygous for the MBOAT7 c.758_778del; p.(Glu253_Ala259del) variant (f) Electropherogram showing the DNA sequence variant (MBOAT7 c.758_778del; p.(Glu253_Ala259del) in a homozygous affected individual (g) Schematic representation of MBOAT7 exons and positions of the genomic variant identified in this study
Clinical features of families 1, 2 & 3
| FAMILY | 1 | 2 | 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Individual | IV-2 | IV-4 | IV-3 | IV-4 | IV-5 | IV-6 | IV-7 | IV-1 | IV-2 |
| Genotype | N/K | N/K | |||||||
| Sex | F | M | M | M | F | F | M | M | F |
| Age at assessment (years) | 20 m | Not assessed (deceased at 18 m) | 20 | 18 | 16 | 19 | 9 | 8y 1 m | 12y |
| Gestation weeks | FT | N/K | FT | FT | N/K | N/K | FT | FT | FT |
| Birth weight kg (SD) | 3.0 (−0.9) | N/K | 3.0 (−1.16) | 2.9 (− 1.38) | N/K | N/K | 2.8 | 1.5 (−4.6) | 1.8 (−3.86) |
| Height cm (SD) | 89 (+ 2.27) | N/K | 172.5 (−0.69) | 168.8 (−1.2) | N/K | N/K | 106.7 (−4.58) | 106.7 (−3.93) | 127 (−3.2) |
| Weight kg (SD) | 8.5 (−2.67) | N/K | 55 (−1.95) | 68 (+ 0.09) | N/K | N/K | 30 (+ 0.34) | N/K | N/K |
| Head circumference cm (SD) | 51 (+ 2.2) | N/K | 50 (−2.8) | 55.5 (−1.03) | 53.6 (− 1.25) | 55.5 (−0.01) | 54 (− 1.9) | 49 (−3.11) | 52 (− 1.81) |
| Development | |||||||||
| Intellectual disability | + | + | Mod-Severe | Severe | Mod-Severe | Mod-Severe | Mod-Severe | Mod-Severe | Mod-Severe |
| Speech delay/impairment | Non-verbal | + | Non-verbal | Non-verbal | + | + | Non-verbal | Non-verbal | Non-verbal |
| Developmental delay | + | + | + | + | + | + | + | + | + |
| Age walking | N/A | N/A | 3.5y | 4y | N/A | N/A | 3.5y | >4y | 4y |
| Neurological features | |||||||||
| Macrocephaly | + | N/K | – | – | – | – | – | – | – |
| Microcephaly | – | N/K | + | – | – | – | – | + | + |
| Seizures | Onset 7 m GTCS Regression | + | Onset 1.5y Focal/ multifocal infantile | Onset 2.5y Focal/ multifocal infantile | Febrile seizures in infancy | Febrile seizures in infancy | Febrile seizures in infancy | Onset in infancy GTCS | Onset in infancy GTCS |
| Hypotonia | + | N/K | + | + | + | + | N/K | + | + |
| Behavioural problems | N/A | N/A | – | Aggressive episodes | – | – | – | Aggressive episodes Hyperactivity | Aggressive episodes |
| Other features | Strabismus Nystagmus Visual loss Hearing loss Hepatosplenomegaly | Deceased aged 1.5 years | Unable to walk | Unable to walk | Reduced physical activity level | ||||
F female, M male, HOM homozygous, FT full-term, N/A Not applicable, N/K not known, m months, y years, +; feature present, −; feature absent, GTCS generalised tonic-clonic seizure
MBOAT7 variants published to date associated with autosomal recessive neurodevelopmental disorder
| Publications | Number of individuals | Number of families | Origin | Transcript | gDNA position [hg38] | cDNA position | Predicted Protein change | Exon | Type | gnomAD frequency (All) |
|---|---|---|---|---|---|---|---|---|---|---|
| Present paper | 7 | 2 | Pakistan | NM_024298.3 | g.54180849_54180869del21 | c.758_778del | p.Glu253_Ala259del | 6 | Inframe deletion | 0.00002333 |
| Johansen et al (2016) | 5 | 2 | Pakistan | NM_024298.3 | g.54180849_54180869del21 | c.758_778del | p.Glu253_Ala259del | 6 | Inframe deletion | 0.00002333 |
| Johansen et al (2016) [ | 4 | 1 | Pakistan | NM_024298.3 | g.54180801_54180807delGGCCGCC | c.820_826del | p.Gly274Profs*47 | 6 | Frameshift | – |
| Johansen et al (2016) [ | 3 | 1 | Egypt | NM_024298.3 | g.54188278_54188297del20 | c.126_145del | p.Leu43Hisfs*69 | 3 | Frameshift | – |
| Johansen et al (2016) [ | 2 | 1 | Jordan | NM_024298.3 | g.54183591delC | c.423delG | p.Leu142Cysfs*8 | 5 | Frameshift | – |
| Johansen et al (2016) [ | 2 | 1 | Iraq | NM_024298.3 | g.54180772C > G | c.854 + 1G > C | p.? | Intron | Splice | – |
| Hu et al (2018) [ | 3 | 1 | Iran | NM_024298.3 | g.54174394C > T | c.1069G > A | p.Gly357Ser | 8 | Missense | 0.00001702 |
| Santos-Cortez et al (2018) [ | 4 | 1 | Pakistan | NM_024298.3 | g.54187242delA | c.251delT | p.Leu84Argfs*25 | Frameshift | – | |
| Yalnizoglu et al (2019) [ | 3 | 1 | Turkey | NM_024298.3 | g.54174186G > A | c.1278G > A | p.Trp426* | 8 | Nonsense | – |
| Yalnizoglu et al (2019) [ | 4 | 2 | Turkey | NM_024298.3 | g.54162440_54174072del | c.? | p.? | 8 | Deletion | – |
| Yalnizoglu et al (2019) [ | 2 | 1 | Turkey | NM_024298.3 | g.54187234C > T | c.259C > T | p.Arg87Gln | 4 | Missense | 0.00001108 |
| Yalnizoglu et al (2019) [ | 2 | 2 | Turkey | NM_024298.3 | g.54180936_54180946del | c.680_690del | p.Leu227Profs*65 | 6 | Frameshift | 0.000004919 |
| Yalnizoglu et al (2019) [ | 1 | 1 | Turkey | NM_024298.3 | g.54174337C > T | c.1126G > A | p.Glu376Lys | 8 | Missense | 0.00003211 |
| Jacher et al. (2019) [ | 1 | 1 | Lebanon | NM_024298.3 | g.54178943 T > C | c.855-2A > G | p.? | Intron | Splice | – |
Clinical features of all published cases associated with biallelic MBOAT7 variants
| Publications | Current study | Johansen et al [ | Hu et al [ | Santos-Cortez et al [ | Yalnizoglu et al [ | Jacher et al [ | Total ( |
|---|---|---|---|---|---|---|---|
| Sex | M = 4, F = 3 | M = 7, F = 9 | M = 3, F = 0 | M = 2, F = 2 | M = 5, F = 7 | M = 0, F = 1 | M = 21, F = 22 |
| Consanguinity | 7/7 (100%) | 16/16 (100%) | 3/3 (100%) | 4/4 (100%) | 12/12 (100%) | 0/1 (0%) | 42/43 (98%) |
| Development | |||||||
| Developmental delay | 7/7 (100%) | 16/16 (100%) | 0/3 (0%) | 4/4 (100%) | 12/12 (100%) | 1/1 (100%) | 40/43 (93%) |
| Speech delay | 7/7 (100%) | 16/16 (100%) | 0/3 (0%) | 4/4 (100%) | 12/12 (100%) | 1/1 (100%) | 40/43 (93%) |
| Non-verbal | 5/7 (71%) | 9/16 (56%) | 0/3 (0%) | N/K | N/K | 0/1 (0%) | 14/27 (52%) |
| Single words | 2/7 (29%) | 7/16 (44%) | N/K | N/K | N/K | 1/1 (100%) | 10/24 (42%) |
| Two word sentences | 0/7 (0%) | 2/16 (13%) | N/K | N/K | 3/12 (25%) | 1/1 (100%) | 6/36 (17%) |
| Motor delay | 7/7 (100%) | 16/16 (100%) | 0/3 (0%) | N/K | 12/12 (100%) | 1/1 (100%) | 36/39 (92%) |
| Never walked | 0/7 (0%) | 3/16 (19%) | 0/3 (0%) | N/K | 0/12 (0%) | 0/1 (0%) | 3/39 (8%) |
| Neurological features | |||||||
| Intellectual disability | 7/7 (100%) | 16/16 (100%) | 3/3 (100%) | 4/4 (100%) | 12/12 (100%) | 1/1 (100%) | 43/43 (100%) |
| Lower than average OFC | 7/7 (100%) | 16/16 (100%) | 0/3 (0%) | 4/4 (100%) | N/K | 0/1 (0%) | 27/31 (87%) |
| Microcephaly | 2/7 (29%) | 6/16 (38%) | 0/3 (0%) | 2/4 (50%) | N/K | 0/1 (0%) | 10/31 (32%) |
| Macrocephaly | 0/7 (0%) | 0/16 (0%) | 0/3 (0%) | 0/4 (0%) | 0/7 (0%) | 1/1 (100%) | 1/43 (2%) |
| Seizures | 6/7 (86%) | 10/16 (63%) | 3/3 (100%) | N/K | 11/12 (92%) | 1/1 (100%) | 31/39 (79%) |
| Generalised tonic clonic | 0/7 (0%) | 1/16 (6%) | N/K | N/K | 2/12 (17%) | 0/1 (0%) | 3/36 (8%) |
| Myoclonic/infantile spasm | 0/7 (0%) | 5/16 (31%) | N/K | N/K | 3/12 (25%) | 0/1 (0%) | 8/36 (22%) |
| Focal | 2/7 (29%) | 2/16 (13%) | N/K | N/K | 1/12 (8%) | 1/1 (100%) | 6/36 (17%) |
| Febrile seizures | 2/7 (29%) | 2/16 (13%) | N/K | N/K | 1/12 (8%) | 0/1 (0%) | 5/36 (14%) |
| Hypotonia | 6/7 (86%) | 15/16 (94%) | N/K | N/K | 12/12 (100%) | 1/1 (100%) | 34/36 (94%) |
| Hypertonia | 0/7 (0%) | 16/16 (100%) | N/K | N/K | 0/12 (0%) | 0/1 (0%) | 16/36 (44%) |
| Behavioural problems/ASD | 3/7 (43%) | 7/16 (44%) | 3/3 (100%) | N/K | 4/12 (33%) | 1/1 (100%) | 18/39 (46%) |
| Poor coordination/ataxic gait | 0/7 (0%) | 0/16 (0%) | N/K | N/K | 11/12 (92%) | N/K | 11/35 (31%) |
| Neuroimaging | 1/7 (14%) | 6/16 (38%) | 1/3 (33%) | N/K | 12/12 (100%) | 1/1 (100%) | 21/39 (54%) |
| Polymicrogyria | 0/1 (0%) | 2/6 (13%) | 0/3 (0%) | N/K | 0/12 (0%) | 0/1 (0%) | 2/23 (9%) |
| Cortical atrophy | 1/1 (100%) | 2/6 (13%) | 0/3 (0%) | N/K | 8/12 (67%) | 0/1 (0%) | 11/23 (45%) |
| Cerebellar dysgenesis | 0/1 (0%) | 0/6 (0%) | 0/3 (0%) | N/K | 8/12 (67%) | 0/1 (0%) | 8/23 (35%) |
| Leukoencepahlopathy | 0/1 (0%) | 0/6 (0%) | 1/1 (100%) | N/K | 0/12 (0%) | 1/1 (100%) | 2/21 (10%) |
| Other features | |||||||
| Strabismus | N/K | N/K | 1/3 (33%) | N/K | 5/12 (42%) | 1/1 (100%) | 7/16 (44%) |
| Retinal/macular degeneration | 0/12 (0%) | N/K | 2/3 (67%) | N/K | N/K | 0/1 (0%) | 2/16 (13%) |
| Optic atrophy | 0/12 (0%) | N/K | 3/3 (100%) | N/K | N/K | 0/1 (0%) | 3/16 (19%) |
| Hyperphagia/obesity | 0/12 (0%) | N/K | 3/3 (100%) | N/K | N/K | 1/1 (100%) | 4/16 (25%) |
| Short stature | 3/7 (43%) | N/K | 0/3 (0%) | N/K | N/K | 0/1 (0%) | 3/11 (27%) |
Comparison of clinical features of all published cases of neurological disorder associated with biallelic MBOAT7 variants, showing number and percentage of individuals (in brackets) with each feature. OFC occipitofrontal circumference, ASD autistic spectrum disorder, N/K not known